Profile data is unavailable for this security.
About the company
Dr. Reddy’s Laboratories Limited is an India-based pharmaceutical company. Its products and services are spread across its core businesses of active pharmaceutical ingredients (APIs), generics, branded generics, biosimilars and over-the-counter (OTC) pharmaceutical products. It works in the areas of gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Its segments consist of Global Generics; Pharmaceutical Services and Active Ingredients (PSAI), and Others. The Global Generics segment consists of the Company's business of manufacturing and marketing prescription and over-the-counter finished pharmaceutical products ready for consumption by the patient, marketed under a brand name (branded formulations) or as generic finished dosages with therapeutic equivalence to branded formulations (generics). The Pharmaceutical Services and Active Ingredients segment consists of the Company's business of manufacturing and marketing APIs and intermediates.
- Revenue in INR (TTM)346.82bn
- Net income in INR55.68bn
- Incorporated1984
- Employees26.94k
- LocationDr Reddy's Laboratories Ltd8-2-337, Road No.3 Banjara HillsHYDERABAD 500-034IndiaIND
- Phone+91 4 049002900
- Fax+91 4 049002999
- Websitehttps://www.drreddys.com/
More ▼
Mergers & acquisitions
| Acquired company | DRREDDY:NSI since announced | Transaction value |
|---|---|---|
| Janssen Pharmaceutica Nv- Stugeron Portfolio | -0.74% | 50.39m |
Data delayed at least 15 minutes, as of Feb 17 2026 10:23 GMT.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Laurus Labs Ltd | 67.22bn | 8.43bn | 546.58bn | 6.17k | 64.86 | -- | 41.72 | 8.13 | 15.61 | 15.61 | 124.44 | -- | -- | -- | -- | 10,899,350.00 | -- | 8.88 | -- | 14.31 | 58.67 | 48.18 | 12.52 | 11.88 | -- | 7.10 | -- | 13.79 | 10.18 | 14.42 | 123.18 | 7.02 | 23.60 | -- |
| Abbott India Ltd | 68.24bn | 15.24bn | 558.64bn | 3.66k | 36.65 | -- | 34.94 | 8.19 | 717.26 | 717.26 | 3,211.47 | -- | -- | -- | -- | 18,650,260.00 | -- | 22.42 | -- | 30.42 | 46.61 | 44.59 | 22.33 | 18.83 | -- | 79.05 | -- | 73.99 | 9.58 | 9.38 | 17.75 | 18.99 | 27.31 | 34.73 |
| Glenmark Pharmaceuticals Ltd | 164.68bn | 10.65bn | 573.01bn | 13.48k | 53.82 | -- | 35.46 | 3.48 | 37.72 | 37.72 | 583.32 | -- | -- | -- | -- | 12,219,440.00 | -- | 1.33 | -- | 1.92 | 71.68 | 60.15 | 6.47 | 1.82 | -- | 16.41 | -- | 39.62 | 12.77 | 4.60 | 155.14 | 6.18 | -4.24 | 0.00 |
| Alkem Laboratories Ltd | 142.53bn | 23.71bn | 655.28bn | 18.64k | 27.64 | -- | 23.31 | 4.60 | 198.32 | 198.32 | 1,192.01 | -- | -- | -- | -- | 7,645,478.00 | -- | 12.12 | -- | 17.53 | 64.05 | 60.06 | 17.00 | 14.69 | -- | 18.13 | -- | 28.96 | 2.34 | 9.21 | 20.59 | 13.95 | 13.22 | 12.47 |
| Aurobindo Pharma Ltd | 331.82bn | 34.87bn | 688.02bn | 9.11k | 19.73 | -- | 13.16 | 2.07 | 60.04 | 60.04 | 571.33 | -- | -- | -- | -- | 36,435,560.00 | -- | 8.62 | -- | 12.13 | 59.35 | 53.55 | 10.50 | 12.38 | -- | 14.24 | -- | 7.25 | 9.39 | 6.55 | 9.86 | 4.15 | 11.98 | -- |
| Mankind Pharma Ltd | 138.42bn | 17.75bn | 860.00bn | 27.00k | 48.51 | -- | 32.12 | 6.21 | 42.95 | 43.05 | 334.94 | -- | -- | -- | -- | 5,126,748.00 | -- | 14.93 | -- | 19.39 | 71.39 | 67.59 | 13.00 | 17.70 | -- | 3.64 | -- | 0.00 | 18.98 | 15.79 | 3.90 | 14.03 | 18.41 | -- |
| Zydus Lifesciences Ltd | 260.89bn | 49.38bn | 916.13bn | 27.92k | 18.55 | -- | 15.09 | 3.51 | 49.08 | 49.08 | 259.31 | -- | -- | -- | -- | 9,345,309.00 | -- | 10.92 | -- | 16.35 | 73.12 | 63.12 | 18.91 | 16.73 | -- | -- | -- | 17.81 | 18.90 | 10.27 | 17.96 | 30.92 | 13.63 | 25.74 |
| Lupin Ltd | 261.51bn | 46.45bn | 1.02tn | 19.98k | 20.45 | -- | 16.95 | 3.88 | 108.62 | 108.62 | 603.92 | -- | -- | -- | -- | 13,088,990.00 | -- | 4.53 | -- | 7.16 | 72.62 | 59.70 | 17.86 | 5.95 | -- | 183.80 | -- | 29.13 | 13.48 | 8.11 | 71.41 | -- | 20.11 | 14.87 |
| Dr Reddy's Laboratories Ltd | 346.82bn | 55.68bn | 1.06tn | 26.94k | 19.00 | -- | 14.13 | 3.05 | 66.81 | 66.81 | 416.15 | -- | -- | -- | -- | 12,871,960.00 | -- | 12.15 | -- | 16.94 | 65.76 | 66.18 | 15.92 | 15.81 | -- | 19.79 | -- | 14.69 | 16.54 | 13.26 | 1.38 | 22.84 | 41.26 | 9.86 |
| Cipla Ltd | 283.51bn | 45.46bn | 1.10tn | 30.31k | 24.11 | -- | 19.68 | 3.86 | 56.26 | 56.26 | 350.81 | -- | -- | -- | -- | 9,352,779.00 | -- | 11.89 | -- | 14.49 | 66.53 | 59.55 | 16.03 | 14.74 | -- | 96.40 | -- | 22.40 | 6.88 | 9.97 | 27.93 | 27.80 | 9.14 | 34.08 |
| Torrent Pharmaceuticals Ltd | 127.42bn | 22.72bn | 1.44tn | 16.11k | 63.49 | -- | 46.76 | 11.32 | 67.12 | 67.12 | 376.38 | -- | -- | -- | -- | 7,910,902.00 | -- | 9.54 | -- | 14.72 | 75.64 | 72.56 | 17.83 | 14.14 | -- | 16.34 | -- | 61.09 | 7.35 | 7.72 | 15.39 | 14.48 | 8.51 | 30.36 |
Data as of Feb 17 2026. Currency figures normalised to Dr Reddy's Laboratories Ltd's reporting currency: Indian Rupee INR
28.16%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Life Insurance Corporation of India (Investment Portfolio)as of 15 Oct 2025 | 85.70m | 10.27% |
| ICICI Prudential Asset Management Co. Ltd. (Invt Mgmt)as of 31 Jan 2026 | 38.43m | 4.61% |
| The Vanguard Group, Inc.as of 04 Feb 2026 | 20.17m | 2.42% |
| Nippon Life India Asset Management Ltd. (Invt Mgmt)as of 05 Feb 2026 | 19.43m | 2.33% |
| BlackRock Fund Advisorsas of 06 Feb 2026 | 14.71m | 1.76% |
| PPFAS Asset Management Private Ltd.as of 31 Jan 2026 | 14.69m | 1.76% |
| SBI Funds Management Ltd.as of 31 Jan 2026 | 12.77m | 1.53% |
| JPMorgan Asset Management (UK) Ltd.as of 05 Feb 2026 | 9.91m | 1.19% |
| Geode Capital Management LLCas of 12 Feb 2026 | 9.84m | 1.18% |
| First Sentier Investors (UK) IM Ltd.as of 31 Aug 2025 | 9.39m | 1.13% |
More ▼
Data from 31 Dec 2025 - 10 Feb 2026Source: FactSet Research Systems Inc.
